


PHARMACEUTICAL 2018



Mirati Therapeutics Inc. Rank 56 of 342





PHARMACEUTICAL 2018



Mirati Therapeutics Inc. Rank 56 of 342



The relative strengths and weaknesses of Mirati Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirati Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 120% points. The greatest weakness of Mirati Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 206%, being 160% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	155,759
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,644
Liabilities, Non-Current	314
Other Assets	962
Other Compr. Net Income	-54
Other Expenses	0
Other Liabilities	0
Other Net Income	1,105
Other Revenues	0
Property and Equipment	525
Research and Development	58,085
Selling, General and Administrative Expense	13,450

Output Variable	Value in 1000 USD
Assets	157,246
Liabilities	13,958
Expenses	71,535
Revenues	0
Stockholders Equity	143,288
Net Income	-70,430
Comprehensive Net Income	-70,457
Economic Capital Ratio	206%

